Skye Bioscience Reports 22.3% Weight Loss at 52 Weeks with Nimacimab Combination Therapy
SKYE sits 52% above its 52-week low of $0.684.
Summary
Skye Bioscience reported strong 52-week interim data for its nimacimab and semaglutide combination therapy, showing 22.3% weight loss and reduced weight regain, positioning it competitively in the obesity market.
Key Events · Product Development and Regulatory · SKYE
-
Significant Weight Loss Achieved
Nimacimab combined with semaglutide achieved a mean weight loss of 22.3% at 52 weeks, with no plateau observed, demonstrating competitive efficacy.
-
Enhanced Durability in Weight Management
The combination therapy reduced weight regain by over 50% during a 13-week off-therapy follow-up compared to semaglutide alone (17.8% vs. 37.3%), indicating improved long-term efficacy.
-
Favorable Safety and Tolerability Profile
The combination treatment maintained a strong safety and tolerability profile over 52 weeks, with no serious adverse events or adverse events of special interest reported.
-
Advancing to Higher-Dose Phase 2b Study
The company plans to advance nimacimab into a Phase 2b study to evaluate higher doses and optimize the regimen, with full topline data from the Phase 2a extension expected in Q3 2026.
Analysis · SKYE · Life Sciences
Skye Bioscience announced highly positive interim 52-week results from its Phase 2a extension study of nimacimab in combination with semaglutide for obesity. The combination achieved a mean weight loss of 22.3% at 52 weeks, with no plateau observed, positioning it competitively against other leading obesity treatments. Crucially, the data also showed a significant reduction in weight regain during off-therapy follow-up, demonstrating enhanced durability compared to semaglutide alone. The therapy maintained a strong safety and tolerability profile. While the company's cash runway extends into Q4 2026, excluding the costs for a planned Phase 2b study, these robust clinical results significantly de-risk future financing efforts and support the advancement of nimacimab into higher-dose studies.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 47.7% of the 235 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SKYE was trading at $1.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.4M. The 52-week trading range was $0.68 to $5.75. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.